| Overview |
| bs-12907R-Cy3 |
| BTBD14A Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Horse, Chicken |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human BTBD14A |
| 401-500/587 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 54813 |
| Nucleus |
| BTB POZ domain containing 14A; BTB domain containing 14A; BTB/POZ domain containing protein 14A; BTB/POZ domain-containing protein 14A; BTBD 14A; BTBD14; NAC-2; NACC2; NACC2_HUMAN; Nucleus accumbens-associated protein 2. |
| BTBD14A is a 587 amino acid protein that contains one BTB/POZ domain. The BTB/POZ domain mediates homomeric and heteromeric POZ-POZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including BCL-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. This suggests that BTBD14A may play a role in transcription regulation. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz